269 related articles for article (PubMed ID: 17353632)
1. [Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
Takenaka M; Okamoto Y; Ikeda K; Hashimoto R; Ueda T; Kurokawa N; Takagi T; Uejima E
Gan To Kagaku Ryoho; 2007 Mar; 34(3):403-7. PubMed ID: 17353632
[TBL] [Abstract][Full Text] [Related]
2. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
3. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Slabý J; Trnený M; Procházka B; Klener P
Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
[TBL] [Abstract][Full Text] [Related]
4. Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in Cisplatin-based chemotherapy: a randomized controlled trial.
Cheirsilpa A; Sinthusake T; Songsakkaesorn A; Visawaprasit S; Chulaka K; Changkuingdee N
Jpn J Clin Oncol; 2005 Dec; 35(12):695-9. PubMed ID: 16319109
[TBL] [Abstract][Full Text] [Related]
5. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
6. Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study.
Shi Y; He X; Yang S; Ai B; Zhang C; Huang D; Dong M; Liu P; Zhou S; Han X
Chemotherapy; 2007; 53(1):44-50. PubMed ID: 17202811
[TBL] [Abstract][Full Text] [Related]
7. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Aksoylar S; Akman SA; Ozgenç F; Kansoy S
Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
[TBL] [Abstract][Full Text] [Related]
8. Granisetron and ondansetron for chemotherapy-related nausea and vomiting.
Zeidman A; Ben Dayan D; Ben Zion T; Kaufman O; Cohen AM; Mittelman M
Haematologia (Budap); 1998; 29(1):25-31. PubMed ID: 9704254
[TBL] [Abstract][Full Text] [Related]
9. Comparison of oral versus intravenous ramosetron in prevention of acute cisplatin-induced emesis: a randomized controlled trial.
Tantipalakorn C; Srisomboon J; Thienthong H; Pantusart A; Suprasert P; Saereesongkhun C; Eamtang S; Sutthichat A; Pautad N
J Med Assoc Thai; 2004 Feb; 87(2):119-25. PubMed ID: 15061293
[TBL] [Abstract][Full Text] [Related]
10. [Antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation].
Park Y; Hatano Y; Sasamoto S; Kato N; Okuyama N; Yamazaki S
Gan To Kagaku Ryoho; 1997 Mar; 24(5):573-7. PubMed ID: 9087290
[TBL] [Abstract][Full Text] [Related]
11. [Preventive effects of ramosetron and granisetron in prevention of gastrointestinal reaction associated with chemotherapeutic agents: a comparative study].
Zhang JD; Liu YP; Teng YE; Shi J
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2058-60. PubMed ID: 14703416
[TBL] [Abstract][Full Text] [Related]
12. [Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord].
Huc P; Block S; Carlier D; Darloy F; Bonneterre ME; Bleuse JP; Fournier C; Bonneterre J
Bull Cancer; 1998 Jun; 85(6):562-8. PubMed ID: 9752283
[TBL] [Abstract][Full Text] [Related]
13. [Clinical study on the inhibitory effect of a 5-HT3 antagonist, granisetron, for nausea and vomiting induced by chemotherapy (CHOP, VEPA, high-dose ETP) for non-Hodgkin's lymphoma].
Sasai Y; Misawa S; Iwai T; Tamura A; Nakazawa N; Ueda Y; Kaneko H; Horiike S; Yokota S; Taniwaki M; Kashima K; Tsuda S; Ookawara Y; Nakao M; Nakagawa H; Fujii H
Gan To Kagaku Ryoho; 1998 Apr; 25(5):723-9. PubMed ID: 9571970
[TBL] [Abstract][Full Text] [Related]
14. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation.
Abbott B; Ippoliti C; Bruton J; Neumann J; Whaley R; Champlin R
Bone Marrow Transplant; 1999 Feb; 23(3):265-9. PubMed ID: 10084258
[TBL] [Abstract][Full Text] [Related]
15. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
Lajolo PP; de Camargo B; del Giglio A
Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119
[TBL] [Abstract][Full Text] [Related]
16. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
[TBL] [Abstract][Full Text] [Related]
17. [A randomized cross-over comparative study of granisetron alone and combination of granisetron, methylprednisolone and droperidol as antiemetic prophilaxis in CDDP-based chemotherapy for gynecologic cancer].
Wataba K; Sagae S; Fukunaka N; Sugimura M; Akutagawa N; Hayashi T; Yamana K; Nakamura T; Terasawa K; Mizumoto H; Kitajima Y; Kudo R
Gan To Kagaku Ryoho; 1997 Apr; 24(6):691-7. PubMed ID: 9126306
[TBL] [Abstract][Full Text] [Related]
18. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer.
Pinarli FG; Elli M; Dagdemir A; Baysal K; Acar S
Pediatr Blood Cancer; 2006 Oct; 47(5):567-71. PubMed ID: 16317736
[TBL] [Abstract][Full Text] [Related]
19. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
Sarcev T; Secen N; Povazan Dj; Sabo A; Popovic J; Bursac D; Kakas M; Zaric B; Milovancev A
J BUON; 2007; 12(2):245-52. PubMed ID: 17600880
[TBL] [Abstract][Full Text] [Related]
20. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community.
Hickok JT; Roscoe JA; Morrow GR; King DK; Atkins JN; Fitch TR
Cancer; 2003 Jun; 97(11):2880-6. PubMed ID: 12767103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]